Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Bluejay Diagnostics ( (BJDX) ) is now available.
On March 13, 2026, Bluejay Diagnostics responded to investor NorthStrive Fund II LP, which had proposed that the company consider acquiring a Phase-1-ready therapeutic program targeting refractory chronic cough to expand its clinical pipeline. Management emphasized that its primary focus remains on progressing the Symphony diagnostic platform, completing the SYMON II study, and managing cash resources to support long-term shareholder value.
The board and management said they will evaluate the suggested acquisition with input from clinical and regulatory advisors to determine whether it is complementary and accretive to the existing platform. They requested additional due diligence materials from NorthStrive and the unnamed counterparty, while stressing that any decision will be guided by fiduciary duties under Delaware law and the interests of current stockholders.
The most recent analyst rating on (BJDX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.
Spark’s Take on BJDX Stock
According to Spark, TipRanks’ AI Analyst, BJDX is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, ongoing losses, and continued cash burn) and a bearish technical setup (below major moving averages with negative MACD). Positive corporate progress on the Symphony IL-6 program and manufacturing readiness provides some offset, but valuation offers limited support given persistent losses and no dividend.
To see Spark’s full report on BJDX stock, click here.
More about Bluejay Diagnostics
Bluejay Diagnostics, Inc. operates in the near-patient critical care diagnostics industry, centered on its Symphony platform and related critical care biomarker menu. The company is currently advancing its SYMON II clinical study, scaling up manufacturing, and preparing for U.S. FDA regulatory submission as it seeks to establish itself as a differentiated platform player in critical care testing.
Average Trading Volume: 237,315
Technical Sentiment Signal: Sell
Current Market Cap: $1.85M
See more insights into BJDX stock on TipRanks’ Stock Analysis page.